Last reviewed · How we verify
Efficacy of the Ranger Drug-Coated Balloon in Treating BTK Lesions in Patients With CLTI
This is a prospective, multicenter, observational study designed to evaluate the clinical outcomes of the Ranger™ SL paclitaxel-coated balloon, a type of drug-coated balloon (DCB), in the treatment of below-the-knee (BTK) lesions in patients with chronic limb-threatening ischemia (CLTI) in China. All enrolled patients will be followed for six months. Patients diagnosed with CLTI who undergo treatment with the Ranger DCB will be included in the study. The primary outcome is the incidence of major adverse events (MAEs).
Details
| Lead sponsor | First Affiliated Hospital, Sun Yat-Sen University |
|---|---|
| Status | NOT_YET_RECRUITING |
| Enrolment | 700 |
| Start date | Mon Jun 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Jan 01 2029 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Chronic Limb Threatening Ischemia
Interventions
- drug-coated balloon
Countries
China